Clinical Scorecard: Multisystem Inflammatory Syndrome in Children: Assessment, Treatment Strategies, and Prognosis

At a Glance

Key Highlights

• MIS-C presents with persistent fever (>38.0°C for >24 hours), shock, and multisystem involvement (≥2 organs) with elevated inflammatory markers.
• Management includes supportive care, immunomodulation with intravenous immunoglobulin (IVIG), corticosteroids, biologics, and thromboprophylaxis.
• Mortality ranges from 1% to 2%, with most patients recovering fully with timely treatment; long-term follow-up is essential for cardiac and other complications.

Guideline-Based Recommendations

Diagnosis

• Diagnosis requires fever, laboratory evidence of inflammation (elevated CRP, ferritin, D-dimer, ESR), and multisystem involvement without alternative diagnosis.
• Diagnostic criteria from CDC and RCPCH emphasize prior SARS-CoV-2 infection or exposure within 2 to 6 weeks.
• Differentiate MIS-C from similar inflammatory conditions such as Kawasaki disease, sepsis, and microbial infections.

Management

• Acute-phase management centers on supportive care and hemodynamic stabilization.
• Immunomodulatory therapy with intravenous immunoglobulin, corticosteroids, and biologic agents forms the therapeutic cornerstone.
• Thromboprophylaxis is frequently warranted due to elevated thromboembolic risk.
• Extracorporeal membrane oxygenation (ECMO) may be considered in refractory cardiorespiratory failure.

Monitoring & Follow-up

• Long-term follow-up is essential to monitor for cardiac, gastrointestinal, and neurologic complications.
• Postrecovery vaccination protocols should be considered.
• Continuous assessment of inflammatory markers and organ function during hospitalization.

Risks

• Potential for severe cardiovascular involvement including shock and cardiac dysfunction.
• Risk of thromboembolic events necessitating thromboprophylaxis.
• Diagnostic ambiguity due to overlap with other inflammatory syndromes.

Patient & Prescribing Data

Children and adolescents diagnosed with MIS-C following SARS-CoV-2 infection

Timely initiation of immunomodulatory therapy (IVIG, corticosteroids, biologics) improves outcomes; thromboprophylaxis is important due to hypercoagulability; ECMO reserved for severe refractory cases.

Clinical Best Practices

• Early recognition and differentiation of MIS-C from other inflammatory conditions to initiate prompt treatment.
• Use of standardized diagnostic criteria incorporating clinical and laboratory findings.
• Multidisciplinary approach including pediatric infectious disease, cardiology, rheumatology, and critical care specialists.
• Close monitoring for cardiac and other organ involvement during acute illness and recovery.
• Implementation of thromboprophylaxis protocols tailored to patient risk.
• Consideration of ECMO in cases of refractory cardiorespiratory failure.

References

• CDC MIS-C Information
• American College of Rheumatology Clinical Guidance for MIS-C
• Royal College of Paediatrics and Child Health Guidance on PIMS-TS